U.S. biopharmaceutical company Harmony Biosciences Holdings, Inc. (Harmony Biosciences) recently announced that its developed drug Wakix® (Pitolisant) has been approved by the U.S. Food and Drug Administration (FDA) for an expanded indication to treat cataplexy in pediatric patients with narcolepsy.

U.S. biopharmaceutical company Harmony Biosciences Holdings, Inc. (Harmony Biosciences) recently announced that its developed drug Wakix® (Pitolisant) has been approved by the U.S. Food and Drug Administration (FDA) for an expanded indication to treat cataplexy in pediatric patients with narcolepsy.

老虎证券2026/02/17 13:17

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This important regulatory decision marks an expansion of the drug's use among pediatric patients, providing a new treatment option for young patients suffering from this rare sleep disorder.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

You may also like

Crypto prices